Citations

Clear

904 citation(s) found for "Gordon, S".

Assessment of Employee Susceptibility to Phishing Attacks at US Health Care Institutions
Gordon, William J. , Wright, Adam , Aiyagari, Ranjit , Corbo, Leslie , Glynn, Robert J. , Kadakia, Jigar, Kufahl, Jack, Mazzone, Christina, Noga, James, Parkulo, Mark A. , Sanford, Brad, Scheib, Paul, Parkulo, Mark, Landman, Adam

Mayo Clinic

JAMA Network Open | March 8, 2019 | Volume: 2 | Issue: 3 | Pages: e190393

10.1001/jamanetworkopen.2019.0393 | PMID 30848810 Get It

Point‐of‐Care Ultrasound for Hospitalists: A Position Statement of the Society of Hospital Medicine
Soni, Nilam J. , Schnobrich, Daniel, Mathews, Benji K., Tierney, David M. , Jensen, Trevor, Dancel, Ria , Cho, Joel, Dversdal, Renee K. , Mints, G. E. , Bhagra, Anjali , Reierson, Kreegan , Kurian, Linda M. , Liu, Gigi , Candotti, Carolina, LoPresti, Charles M. , Wong, Tanping , Johnson, Gordon E., Maw, Anna , Franco‐Sadud, Ricardo, Lucas, Brian , Boesch, Brandon, Lenchus, Joshua D. , Soni, Nilam J

Mayo Clinic

Journal of Hospital Medicine | February 26, 2019 | Volume: 14 | Issue: 1 | Pages: No page available

10.12788/jhm.3079 | PMID 30604779 Get It

Many hospitalists incorporate point‐of‐care ultrasound (POCUS) into their daily practice to answer specific diagnostic questions or to guide performance of invasive bedside procedures. However, standards for hospitalists in POCUS training and assessment are not yet established. Most internal medicine residency training programs, the major pipeline for incoming hospitalists, have only recently begun to incorporate POCUS in their curricula. The purpose of this document is to inform a broad audience on what POCUS is and how hospitalists are using it. This document is intended to provide guidance for the hospitalists who use POCUS and administrators who oversee its use. We discuss POCUS 1) applications, 2) training, 3) assessments, and 4) program management. Practicing hospitalists must continue to collaborate with their local credentialing bodies to outline requirements for POCUS use. Hospitalists should be integrally involved in decision‐making processes surrounding POCUS program management.
Comparison of Pittsburgh compound B and florbetapir in cross‐sectional and longitudinal studies
Flores, Shaney , Wang, Guoqiao , Hornbeck, Russ C. , Speidel, Benjamin , Joseph‐Mathurin, Nelly , Vlassenko, Andrei G. , Gordon, Brian A. , Klunk, William E. , Jack, Clifford R. , Farlow, Martin R. , Salloway, Stephen , Snider, Barbara J., Berman, Sarah , Roberson, Erik D. , Brosch, Jared R. , Jimenez-Velazques, Ivonne, Dyck, Christopher H. van , Yuan, Shauna H. , Jayadev, Suman , Gauthier, Serge , Hsiung, Ging‐Yuek Robin , Brooks, William S. , Fulham, Michael , Clarnette, Roger, Masters, Colin L. , Wallon, David , Hannequin, Didier , Dubois, Bruno , Pariente, Jérémie , Sánchez‐Valle, Raquel , Mummery, Catherine J. , Ringman, John M. , Klein, Gregory , Milosavljevic‐Ristic, Smiljana, Morris, John C. , Bateman, Randall J. , Jack, Clifford R , Gordon, Brian A , Hsiung, Gink-Yuek , Roberson, Erik , Sánchez-Valle, Raquel , Bateman, Randall J , Masters, Colin L , Joseph-Mathurin, Nelly , Morris, John C , Brooks, William , Su, Yi , Koeppe, Robert A. , Galasko, Douglas , Honig, Lawrence S. , Masellis, Mario , Bottlaender, Michel , McDade, Eric , Xiong, Chengjie , Benzinger, Tammie L.S. , Berman, Sarah

Mayo Clinic

Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring | February 23, 2019 | Volume: 11 | Issue: 1 | Pages: 180-190

10.1016/j.dadm.2018.12.008 | PMID 30847382 Get It

Abstract Introduction Quantitative in vivo measurement of brain amyloid burden is important for both research and clinical purposes. However, the existence of multiple imaging tracers presents challenges to the interpretation of such measurements. This study presents a direct comparison of Pittsburgh compound B–based and florbetapir‐based amyloid imaging in the same participants from two independent cohorts using a crossover design. Methods Pittsburgh compound B and florbetapir amyloid PET imaging data from three different cohorts were analyzed using previously established pipelines to obtain global amyloid burden measurements. These measurements were converted to the Centiloid scale to allow fair comparison between the two tracers. The mean and inter‐individual variability of the two tracers were compared using multivariate linear models both cross‐sectionally and longitudinally. Results Global amyloid burden measured using the two tracers were strongly correlated in both cohorts. However, higher variability was observed when florbetapir was used as the imaging tracer. The variability may be partially caused by white matter signal as partial volume correction reduces the variability and improves the correlations between the two tracers. Amyloid burden measured using both tracers was found to be in association with clinical and psychometric measurements. Longitudinal comparison of the two tracers was also performed in similar but separate cohorts whose baseline amyloid load was considered elevated (i.e., amyloid positive). No significant difference was detected in the average annualized rate of change measurements made with these two tracers. Discussion Although the amyloid burden measurements were quite similar using these two tracers as expected, difference was observable even after conversion into the Centiloid scale. Further investigation is warranted to identify optimal strategies to harmonize amyloid imaging data acquired using different tracers.
Evaluation of Accepting Kidneys of Varying Quality for Transplantation or Expedited Placement With Decision Trees
Kilambi, Vikram , Bui, Kevin , Hazen, Gordon B. , Ladner, Daniela P. , Ladner, Daniela P , Friedewald, John J. , Kaplan, Bruce , Mehrotra, Sanjay

Mayo Clinic

Transplantation | February 2, 2019 | Volume: 103 | Issue: 5 | Pages: 980-989

10.1097/tp.0000000000002585 | PMID 30720682 Get It

Background. Underutilization of marginal-quality kidneys for transplantation produced ideas of expediting kidney placement for populations with decreased opportunities of receiving transplants. Such policies can be less efficacious for specific individuals and should be scrutinized until the decision-making for accepting marginal-quality organs, which has relied on experiential judgment, is better understood at the individual level. There exist rigorous tools promoting personalized decisions with useful and objective information. Methods. This article introduces a decision-tree methodology that analyzes a patient’s dilemma: to accept a kidney offer now or reject it. The methodology calculates the survival benefit of accepting a kidney given a certain quality now and the survival benefit of rejecting it. Survival benefit calculation accounts for patients’ and donors’ characteristics and transplant centers’ and organ procurement organizations’ performances and incorporates patients’ perceived transplant and dialysis utilities. Valuations of rejecting an offer are contingent on future opportunities and subject to uncertainty in the timing of successive kidney offers and their quality and donor characteristics. Results. The decision tree was applied to a realistic patient profile as a demonstration. The tool was tested on 1000 deceased-donor kidney offers in 2016. Evaluating up to 1 year of future offers, the tool attains 61% accuracy, with transplant utility of 1.0 and dialysis utility of 0.5. The accuracy reveals potential bias in kidney offer acceptance/rejection at transplant centers. Conclusions. The decision-tree tool presented could aid personalized transplant decision-making in the future by providing patients with calculated, individualized survival benefits between accepting and rejecting a kidney offer.
Abstract TP527: Baseline Physical Activity Profiles in CREST-2 Trial Participants
Voeks, Jenifer H. , Chimowitz, Marc I. , Barrett, Kevin M. , Brown, Robert D. , Lazar, Ronald M. , Moore, Wesley S. , Moy, Claudia S., Roubin, Gary S., Foster, Malcolm , Wechsler, Lawrence R. , Lal, Brajesh K. , Brott, Thomas G. , Chaturvedi, Seemant , Turan, Tanya N. , Gordon, Neil F. , Howard, Virginia J. , Howard, George , Demaerschalk, Bart M. , Meschia, James F.

Mayo Clinic

Stroke | January 30, 2019 | Volume: 50 | Issue: Suppl_1 | Pages: No page available

10.1161/str.50.suppl_1.tp527 Get It

Background: The importance of physical activity in preventing major vascular events has received increased attention in the past decade. Due to the inclusion of the INTERVENT lifestyle modification program, the CREST2 trial provides a unique opportunity to study physical activity profiles in patients with severe asymptomatic extracranial carotid stenosis. Hypothesis: Based on data from a trial of intracranial stenosis patients, we aimed to evaluate the hypothesis that <40% of carotid stenosis subjects will have optimal physical activity levels. We also assessed key subgroups to determine patterns of physical activity. Methods: We analyzed 1087 CREST2 participants with baseline data on physical activity. The Physician-based Assessment and Counseling for Exercise (PACE) score is recorded for each patient and dichotomized as “in target” (4-8 points) or “out of target” (<4 points). A PACE score of <4 indicates a subject who does not engage in regular exercise. Results are analyzed for the entire trial. Chi square testing and t-tests were performed for evaluation of subgroup differences. Results: The mean age of the study population is 69.5±7.8 years (60% male). The median PACE score at baseline is 4.0 (mean 3.8±2.1; IQR 2 to 6). The Table shows baseline characteristics of patients by mean PACE score. Being male, not having diabetes mellitus, having a body mass index <30kg/m2, being a non-smoker, and not having a history of peripheral arterial disease were associated with significantly higher mean PACE scores (P<0.01). Conclusions: We have defined several patient groups with asymptomatic carotid stenosis that have suboptimal physical activity. These results provide opportunities for targeted efforts to improve primary stroke prevention. These baseline data will also allow investigators to determine if trial involvement and the INTERVENT program leads to improvement in the level of physical activity.
Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma
Ramchandren, Radhakrishnan , Advani, Ranjana H. , Ansell, Stephen M. , Bartlett, Nancy L. , Chen, Robert , Connors, Joseph M. , Feldman, Tatyana , Forero‐Torres, Andres , Friedberg, Jonathan W. , Gopal, Ajay K. , Younes, Anas , Engley, Gerald, Manley, Thomas, Fenton, Keenan , Straus, David J. , Gordon, Leo I , Connors, Joseph M , Bartlett, Nancy L , Advani, Ranjana H , Gopal, Ajay , Gordon, Leo I. , Kuruvilla, John , Savage, Kerry J.

Mayo Clinic

Clinical Cancer Research | January 7, 2019 | Volume: 25 | Issue: 6 | Pages: 1718-1726

10.1158/1078-0432.ccr-18-2435 | PMID 30617130 Get It

Abstract Purpose: To evaluate safety and efficacy outcomes for subjects on the ECHELON-1 study treated in North America (NA). Patients and Methods: ECHELON-1 is a global, open-label, randomized phase III study comparing doxorubicin, vinblastine, and dacarbazine in combination with brentuximab vedotin (A+AVD) versus ABVD (AVD + bleomycin) as first-line therapy in subjects with stage III or IV classical Hodgkin lymphoma (cHL; NCT01712490). Subjects were randomized 1:1 to receive A+AVD or ABVD intravenously on days 1 and 15 of each 28-day cycle for up to 6 cycles. Results: The NA subgroup consisted of 497 subjects in the A+AVD (n = 250) and ABVD (n = 247) arms. Similar to the primary analysis based on the intent-to-treat population, the primary endpoint [modified progression-free survival (PFS) per independent review] demonstrated an improvement among subjects who received A+AVD compared with ABVD (HR = 0.60; P = 0.012). For PFS, the risk of progression or death was also reduced (HR = 0.50; P = 0.002). Subsequent anticancer therapies were lower in the A+AVD arm. Grade 3 or 4 adverse events (AEs) were more common, but there were fewer study discontinuations due to AEs in the A+AVD arm as compared with ABVD. Noted differences between arms included higher rates of febrile neutropenia (20% vs. 9%) and peripheral neuropathy (80% vs. 56%), but lower rates of pulmonary toxicity (3% vs. 10%) in subjects treated with A+AVD versus ABVD. Conclusions: The efficacy benefit and manageable toxicity profile observed in the NA subgroup of ECHELON-1 support A+AVD as a frontline treatment option for patients with stage III or IV cHL.
Probing the Virtual Proteome to Identify Novel Disease Biomarkers
Smith, J. G. , Melander, Olle , Ngo, Debby , Shaffer, Christian M., Ferguson, Jane F. , Herzig, Matthew , McCarty, Catherine A. , Jarvik, Gail P. , Gordon, Allan , Palmer, Melody R. , Crosslin, David R. , Larson, Eric B. , Pacheco, Jennifer A. , Peissig, Peggy , Brilliant, Murray H. , Kitchner, Terrie, Linneman, James G., Namjou, Bahram , Ritchie, Marylyn D. , Borthwick, Kenneth M., Kiryluk, Krzysztof , Mentch, Frank , Sleiman, Patrick , Karlson, Elizabeth W. , Zhu, Yineng, Denny, Joshua C. , Roden, Dan M. , Gerszten, Robert E. , Wang, Thomas J. , Denny, Joshua C , Jarvik, Gail P , Gordon, Adam S , Pacheco, Jennifer A , Kiryluk, Krzysztof , Ferguson, Jane F , Mosley, Jonathan D , Benson, Mark D. , Chute, Christopher G. , Carrell, David , Kullo, Iftikhar J. , Williams, Marc S , Verma, Shefali S. , Vasan, Ramachandran S. , Yang, Qiong , Roden, Dan M. , Smith, J Gustav

Mayo Clinic

Circulation | January 7, 2019 | Volume: 138 | Issue: 22 | Pages: 2469-2481

10.1161/circulationaha.118.036063 | PMID 30571344 Get It

Background: Proteomic approaches allow measurement of thousands of proteins in a single specimen, which can accelerate biomarker discovery. However, applying these technologies to massive biobanks is not currently feasible because of the practical barriers and costs of implementing such assays at scale. To overcome these challenges, we used a “virtual proteomic” approach, linking genetically predicted protein levels to clinical diagnoses in >40 000 individuals. Methods: We used genome-wide association data from the Framingham Heart Study (n=759) to construct genetic predictors for 1129 plasma protein levels. We validated the genetic predictors for 268 proteins and used them to compute predicted protein levels in 41 288 genotyped individuals in the Electronic Medical Records and Genomics (eMERGE) cohort. We tested associations for each predicted protein with 1128 clinical phenotypes. Lead associations were validated with directly measured protein levels and either low-density lipoprotein cholesterol or subclinical atherosclerosis in the MDCS (Malmö Diet and Cancer Study; n=651). Results: In the virtual proteomic analysis in eMERGE, 55 proteins were associated with 89 distinct diagnoses at a false discovery rate q<0.1. Among these, 13 associations involved lipid (n=7) or atherosclerosis (n=6) phenotypes. We tested each association for validation in MDCS using directly measured protein levels. At Bonferroni-adjusted significance thresholds, levels of apolipoprotein E isoforms were associated with hyperlipidemia, and circulating C-type lectin domain family 1 member B and platelet-derived growth factor receptor-β predicted subclinical atherosclerosis. Odds ratios for carotid atherosclerosis were 1.31 (95% CI, 1.08–1.58; P =0.006) per 1-SD increment in C-type lectin domain family 1 member B and 0.79 (0.66–0.94; P =0.008) per 1-SD increment in platelet-derived growth factor receptor-β. Conclusions: We demonstrate a biomarker discovery paradigm to identify candidate biomarkers of cardiovascular and other diseases.
PD-L1 expression in non-clear cell renal cell carcinoma and benign kidney tumors.
Fay, André P. , Gray, Kathryn P. , Song, Jiaxi , Carvo, Ingrid, Lampron, Megan E., Albigès, Laurence , Stanton, Melissa, Freeman, Gordon J. , Hirsch, Michelle S. , Callea, Marcella , Ho, Thai H. , McDermott, David F. , Atkins, Michael B. , Signoretti, Sabina , Choueiri, Toni K.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 4526-4526

10.1200/jco.2014.32.15_suppl.4526 Get It

Should Researchers Offer Results to Family Members of Cancer Biobank Participants? A Mixed-Methods Study of Proband and Family Preferences
Gordon, Deborah R., Breitkopf, Carmen Radecki , Robinson, Marguerite , Petersen, Wesley O., Egginton, Jason S. , Chaffee, Kari G. , Petersen, Gloria M. , Koenig, Barbara A. , Rabe, Kari G. , Wolf, Susan M.

Mayo Clinic

AJOB Empirical Bioethics | December 31, 2018 | Volume: 10 | Issue: 1 | Pages: 1-22

10.1080/23294515.2018.1546241 | PMID 30596322 Get It